Here’s Why Growth Of Novocure’s Brain Cancer Treatment Is Only Just Starting
Glioblastoma is the most invasive and malignant type of brain cancer. If untreated, patients survive for a medial duration of merely three to four months from the initial development of tumors. The condition affects more than 27,000 adults in North America annually.
Since 2015, Novocure (NASDAQ: NVCR) has commercialized a medical device called Tumor Treating Fields (TTF) which can significantly prolong the survival rates of patients when combined with other standards of care. Sales of the product have amounted to more than nine figures last year, and may skyrocket to new levels as the company begins to investigate the medical device for expanded use against other types of cancer. Let's examine the company's growth catalysts below.
IMAGE SOURCE: GETTY IMAGES
Source Fool.com
